Evidence map›Paper›PMID 30408064›Full record

ArticlePloS one2018

Role of variant allele fraction and rare SNP filtering to improve cellular DNA repair endpoint association.

David M Vossen, Caroline V M Verhagen, Reidar Grénman, Roelof J C Kluin, Marcel Verheij, Michiel W M van den Brekel, Lodewyk F A Wessels, Conchita Vens

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

David M VossenDivision of Cell Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Caroline V M VerhagenDivision of Cell Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Reidar GrénmanDepartment of Otorhinolaryngology-Head and Neck Surgery, Hospital and University of Turku, Turku, Finland.
Roelof J C KluinGenomics Core Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0002-5133-142X
Marcel VerheijDepartment of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Michiel W M van den BrekelInstitute of Phonetic Sciences, University of Amsterdam, Amsterdam, The Netherlands.
Lodewyk F A WesselsDivision of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Conchita VensDivision of Cell Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0002-8608-7236
The Netherlands Cancer Institute · NLAmsterdam UMC Location University of Amsterdam · NLUniversity of Turku · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLarge cancer genome studies continue to reveal new players in treatment response and tumorigenesis. The discrimination of functional alterations from the abundance of passenger genetic alterations still poses challenges and determines DNA sequence variant selection procedures. Here we evaluate variant selection strategies that select homozygous variants and rare SNPs and assess its value in detecting tumor cells with DNA repair defects.

methodsTo this end we employed a panel of 29 patient-derived head and neck squamous cell carcinoma (HNSCC) cell lines, of which a subset harbors DNA repair defects. Mitomycin C (MMC) sensitivity was used as functional endpoint of DNA crosslink repair deficiency. 556 genes including the Fanconi anemia (FA) and homologous recombination (HR) genes, whose products strongly determine MMC response, were capture-sequenced.

resultsWe show a strong association between MMC sensitivity, thus loss of DNA repair function, and the presence of homozygous and rare SNPs in the relevant FA/HR genes. Excluding such selection criteria impedes the discrimination of crosslink repair status by mutation analysis. Applied to all KEGG pathways, we find that the association with MMC sensitivity is strongest in the KEGG FA pathway, therefore also demonstrating the value of such selection strategies for exploratory analyses. Variant analyses in 56 clinical samples demonstrate that homozygous variants occur more frequently in tumor suppressor genes than oncogenes further supporting the role of a homozygosity criterion to improve gene function association or tumor suppressor gene identification studies.

conclusionTogether our data show that the detection of relevant genes or of repair pathway defected tumor cells can be improved by the consideration of allele zygosity and SNP allele frequencies.

Indexed as

Polymorphism, Single NucleotideAllelesCell Line, TumorDNA, NeoplasmDNA RepairFanconi Anemia Complementation Group ProteinsGenes, Tumor SuppressorGenetic VariationHead and Neck NeoplasmsHomozygoteHumansLoss of HeterozygosityMitomycinRecombinational DNA RepairSquamous Cell Carcinoma of Head and NeckDNA, NeoplasmFanconi Anemia Complementation Group ProteinsMitomycin

Identifiers

PMID30408064
PMCPMC6224072
OpenAlexW2900426420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.